Proactive versus reactive inhibition in ADHD: Genetics, Neurobiology and pharmacology

Proactive versus reactive inhibition in ADHD: Genetics, Neurobiology and pharmacology - Proactive versus reactive inhibition in ADHD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41454

Enrollment

Registered

2012-06-08

Start date

2013-04-10

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aandachtstekortstoornis ADHD

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Children diagnosed with ADHD according to DSM IV criteria Age between 8-16 Willing to discontinue methylphenidate 48 hours before testing IQ above 75

Exclusion criteria

Exclusion criteria: History of or present neurological disorder One or more of the following comorbid disorders are diagnosed: generalized anxiety disorder, depression, tics, psychosis or autism IQ below 75

Design outcomes

Primary

Measure	Time frame
The primary outcomes of this study are (1) Stop-associated ERP measures at baseline (N1 and P3) (objective 1.1) (2) Stop-associated fMRI measures at baseline (activitity in IFG an SFG) (objective 1.2) (3) DAT1 and COMT genotype (objective 1.3)	—

Secondary

Measure	Time frame
The secondary outcomes of this study are (1) Coherence of brain activity from EEG (objective 2.1) (2) Connectivity between IFG and SFG from RS-MRI (objective 2.2)	—

Countries

Netherlands

Outcome results